ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Celltrion, Inc.

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.


Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.


In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.


Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2022 KRWUSD
Gross Profit991,885.35M767.65M
Operating income647,199.86M500.88M
Income before tax619,117.32M479.15M
Net income526,616.03M407.56M
Diluted EPS3,680.882.84
Dividends Per Share360.570.27
Total Assets5,891.65B4,659.27M
Total liabilities1,617.44B1,279.12M
Total equity4,139.36B3,273.51M
Operating cash flow-8,939.24M-6.91M
Currency in KRWCurrency in USD

Historical Data

 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 982,074.95M 1,128.45B 1,849.11B 1,893.40B 2,283.96B
Gross Profit 544,684.88M 623,118.64M 1,016.64B 1,050.66B 991,885.35M
Operating income 322,728.11M 381,535.86M 718,579.05M 744,162.54M 647,199.86M
Income before tax 302,159.30M 382,510.47M 654,561.59M 742,209.04M 619,117.32M
Net income 245,755.01M 301,030.34M 517,759.53M 569,488.02M 526,616.03M
EBITDA 447,554.58M 535,255.48M 892,388.45M 958,322.27M 822,487.46M
Diluted EPS 1,652.66 2,074.44 3,560.57 3,981.47 3,680.88
Dividends Per Share 0 0 0 707.01 360.57
Total Assets 3,590.82B 3,859.64B 5,020.12B 5,674.12B 5,891.65B
Total liabilities 992,561.59M 983,733.41M 1,589.54B 1,620.74B 1,617.44B
Total equity 2,486.50B 2,760.10B 3,307.67B 3,917.23B 4,139.36B
Operating cash flow 354,768.82M 468,031.66M 342,017.88M 901,686.05M -8,939.24M
 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 892.37M 967.65M 1,567.19M 1,653.39M 1,767.63M
Gross Profit 494.93M 534.32M 861.64M 917.48M 767.65M
Operating income 293.25M 327.16M 609.02M 649.83M 500.88M
Income before tax 274.56M 328.00M 554.76M 648.12M 479.15M
Net income 223.30M 258.13M 438.82M 497.30M 407.56M
EBITDA 406.67M 458.98M 756.33M 836.84M 636.55M
Diluted EPS 1.50 1.77 3.01 3.47 2.84
Dividends Per Share 0 0 0 0.61 0.27
Total Assets 3,218.15M 3,337.49M 4,621.30M 4,773.18M 4,659.27M
Total liabilities 889.55M 850.64M 1,463.26M 1,363.40M 1,279.12M
Total equity 2,228.44M 2,386.70M 3,044.90M 3,295.25M 3,273.51M
Operating cash flow 322.36M 401.33M 289.87M 787.38M -6.91M

Valuation Measures

Dec 2022
Operating margin28.33%
Profit margin23.05%


  • Chief Executive Officer & Director: Wu-Sung Ki
  • Finance Director: Ho-Seop Lee
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Sang-Joon Lee
  • Vice President: Jung-Won Yoon


  • SEO JUNG-JIN (22.1%)
  • National Pension Service of Korea (7.4%)
  • Temasek Holdings Pte Ltd. (Investment Management) (4.1%)
  • Celltrion, Inc. (2.6%)
  • The Vanguard Group, Inc. (2.5%)
  • BlackRock Fund Advisors (1.6%)
  • Norges Bank Investment Management (1.1%)
  • Mirae Asset Global Investments Co., Ltd. (1.0%)
  • Samsung Asset Management Co., Ltd. (0.7%)
  • BlackRock Advisors (UK) Ltd. (0.5%)

Contact Details

Related Companies

  • Celltrion Asia Pacific Pte Ltd.
  • Celltrion Group Hong Kong Ltd.
  • Celltrion Biopharma Ltd.
  • Celltrion Global Safety Data Center, Inc.
  • Celltrion Europe Ltd.
  • Vcell Healthcare Ltd.
  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.


  • Hikma Pharmaceuticals Plc
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Amgen Inc.
  • Pfizer Inc.
  • AstraZeneca PLC
  • Bio-Thera Solutions, Ltd. Class A
  • Gilead Sciences, Inc.
  • Fresenius SE & Co. KGaA
  • Sanofi
  • Coherus BioSciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • GSK plc
  • LG Chem Ltd.
  • Otsuka Holdings Co., Ltd.
  • Sam Chun Dang Pharm. Co., Ltd.
  • Chemical Works of Gedeon Richter Plc
  • Viatris, Inc.
  • Formycon AG
  • JW Pharmaceutical Corporation
  • Reyon Pharmaceutical Co., Ltd.
  • PharmGen Science, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • EirGenix Inc
  • PharmAbcine Inc.
  • Bukwang Pharmaceutical Co., Ltd.
  • Greenwich LifeSciences, Inc.
  • Prestige Biologics Co., Ltd.
Last Updated on 21 Sep, 2023

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more